Kenya

Population 2018: 51 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>150 (92–222)</td>
<td>292 (179–432)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>40 (25–60)</td>
<td>79 (48–117)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>2.3 (1.1–4.1)</td>
<td>4.5 (2.1–7.9)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>19 (11–30)</td>
<td>38 (22–59)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>13 (8.1–20)</td>
<td>26 (16–38)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 1.3% (0.74–2)
- Previously treated cases: 4.4% (3.7–5.2)

TB case notifications, 2018

- Total new and relapse: 94 534
  - % tested with rapid diagnostics at time of diagnosis: 47%
  - % with known HIV status: 98%
  - % pulmonary: 85%
  - % bacteriologically confirmed**: 58%
  - % children aged 0–14 years: 10%
  - % women: 32%
  - % men: 58%

Total cases notified: 96 478

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 63% (43–100)
- TB patients facing catastrophic total costs, 2017: 27% (21–32)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 23% (12–36)

TB/HIV care in new and relapse TB patients, 2018

- Patients with known HIV status who are HIV-positive: 24 950 (27%)
  - on antiretroviral therapy: 24 186 (97%)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**: 64%
  - New cases: 64%
  - Previously treated cases: 79%

Laboratory-confirmed cases*:

- MDR/RR-TB: 465, XDR-TB: 1
- MDR/RR-TB cases tested for resistance to second-line drugs: 125

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 83% (83 088)
- Previously treated cases, excluding relapse, registered in 2017: 72% (1 583)
- HIV-positive TB cases registered in 2017: 78% (23 060)
- MDR/RR-TB cases started on second-line treatment in 2016: 66% (308)
- XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 34% (31–37)

TB cases on preventive treatment

TB financing, 2019

- National TB budget (US$ millions): 81
  - Funding source: 22% domestic, 15% international, 63% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-10